Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972 - 2Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
- 3Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 4Artemis moon mission breaks record for distance from Earth
- 5As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- 7 Popular Vacation destinations In China
- Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- Broken toilet, T-shirts on windows and collecting saliva: The weirdness of daily life aboard Orion
- Why most Jewish Israelis back the death penalty for terrorists
- Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
